Defining the DNA Substrate Binding Sites on HIV-1 Integrase

Journal of Molecular Biology

Volumn 385, Issue 2, 2009, Pages 568-579

  Dolan, James ^a   Chen, Aiping ^a   Weber, Irene T ^b   Harrison, Robert W ^b   Leis, Jonathan ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

DNA; HIV 1; integrase; model structure

Indexed keywords

INTEGRASE; LENS EPITHELIUM DERIVED GROWTH FACTOR; PROTEIN P75; TETRAMER; VIRUS DNA; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ARTICLE; AVIAN SARCOMA VIRUS; CROSS LINKING; DNA DETERMINATION; DNA STRAND; DNA TRANSFER; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; GENE TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LONG TERMINAL REPEAT; MASON PFIZER MONKEY VIRUS; MOLECULAR MODEL; MOLECULAR RECOGNITION; MUTATION; NONHUMAN; NUCLEOTIDE BINDING SITE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; SEQUENCE HOMOLOGY;

AVIAN SARCOMA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LEIS; MASON-PFIZER MONKEY VIRUS;

EID: 58149091892     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.10.083     Document Type: Article

References (71)

1. Katz R.A., Merkel G., Kulkosky J., Leis J., and Skalka A.M. The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro. Cell 63 (1990) 87-95
2. Li M., and Craigie R. Processing of viral DNA ends channels the HIV-1 integration reaction to concerted integration. J. Biol. Chem. 280 (2005) 29334-29339
3. Sinha S., and Grandgenett D.P. Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells. J. Virol. 79 (2005) 8208-8216
4. Chen A., Weber I.T., Harrison R.W., and Leis J. Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat ends. J. Biol. Chem. 281 (2006) 4173-4182
5. Snasel J., Krejcik Z., Jencova V., Rosenberg I., Ruml T., Alexandratos J., et al. Integrase of Mason-Pfizer monkey virus. FEBS J. 272 (2005) 203-216
6. De Lano W.L. The PyMol Molecular Graphics System v1.00 edit (2002)
7. Heuer T.S., and Brown P.O. Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking. Biochemistry 36 (1997) 10655-10665
8. Bischerour J., Tauc P., Leh H., de Rocquigny H., Roques B., and Mouscadet J.F. The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA. Nucleic Acids Res. 31 (2003) 2694-2702
9. Engelman A., Liu Y., Chen H., Farzan M., and Dyda F. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. J. Virol. 71 (1997) 3507-3514
10. Zhu K., Dobard C., and Chow S.A. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J. Virol. 78 (2004) 5045-5055
11. Villanueva R.A., Jonsson C.B., Jones J., Georgiadis M.M., and Roth M.J. Differential multimerization of Moloney murine leukemia virus integrase purified under nondenaturing conditions. Virology 316 (2003) 146-160
12. Fikkert V., Van Maele B., Vercammen J., Hantson A., Van Remoortel B., Michiels M., et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 77 (2003) 11459-11470
13. Hazuda D.J., Anthony N.J., Gomez R.P., Jolly S.M., Wai J.S., Zhuang L., et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl Acad. Sci. USA 101 (2004) 11233-11238
14. Cherepanov P., Ambrosio A.L., Rahman S., Ellenberger T., and Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl Acad. Sci. USA 102 (2005) 17308-17313
15. Busschots K., Vercammen J., Emiliani S., Benarous R., Engelborghs Y., Christ F., and Debyser Z. The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. J. Biol. Chem. 280 (2005) 17841-17847
16. Rahman S., Lu R., Vandegraaff N., Cherepanov P., and Engelman A. Structure-based mutagenesis of the integrase-LEDGF/p75 interface uncouples a strict correlation between in vitro protein binding and HIV-1 fitness. Virology 357 (2007) 79-90
17. Raghavendra N.K., and Engelman A. LEDGF/p75 interferes with the formation of synaptic nucleoprotein complexes that catalyze full-site HIV-1 DNA integration in vitro: implications for the mechanism of viral cDNA integration. Virology 360 (2007) 1-5
18. Llano M., Saenz D.T., Meehan A., Wongthida P., Peretz M., Walker W.H., et al. An essential role for LEDGF/p75 in HIV integration. Science 314 (2006) 461-464
19. Llano M., Vanegas M., Hutchins N., Thompson D., Delgado S., and Poeschla E.M. Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. J. Mol. Biol. 360 (2006) 760-773
20. Ciuffi A., and Bushman F.D. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet. 22 (2006) 388-395
21. Vanegas M., Llano M., Delgado S., Thompson D., Peretz M., and Poeschla E. Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering. J. Cell Sci. 118 (2005) 1733-1743
22. Konsavage Jr. W.M., Burkholder S., Sudol M., Harper A.L., and Katzman M. A substitution in rous sarcoma virus integrase that separates its two biologically relevant enzymatic activities. J. Virol. 79 (2005) 4691-4699
23. Gerton J.L., Ohgi S., Olsen M., DeRisi J., and Brown P.O. Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions. J. Virol. 72 (1998) 5046-5055
24. Al-Mawsawi L.Q., Sechi M., and Neamati N. Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivity. FEBS Lett. (2007)
25. Al-Mawsawi L.Q., Fikkert V., Dayam R., Witvrouw M., Burke Jr. T.R., Borchers C.H., and Neamati N. Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proc. Natl Acad. Sci. USA 103 (2006) 10080-10085
26. Al-Mawsawi L.Q., Hombrouck A., Dayam R., Debyser Z., and Neamati N. Four-tiered pi interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity. Virology 377 (2008) 355-363
27. Faure A., Calmels C., Desjobert C., Castroviejo M., Caumont-Sarcos A., Tarrago-Litvak L., et al. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res. 33 (2005) 977-986
28. Van Maele B., Busschots K., Vandekerckhove L., Christ F., and Debyser Z. Cellular co-factors of HIV-1 integration. Trends Biochem. Sci. 31 (2006) 98-105
29. Cherepanov P., Maertens G., Proost P., Devreese B., Van Beeumen J., Engelborghs Y., et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278 (2003) 372-381
30. Li M., Mizuuchi M., Burke Jr. T.R., and Craigie R. Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J. 25 (2006) 1295-1304
31. Vora A., and Grandgenett D.P. DNase protection analysis of retrovirus integrase at the viral DNA ends for full-site integration in vitro. J. Virol. 75 (2001) 3556-3567
32. Jenkins T.M., Engelman A., Ghirlando R., and Craigie R. A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J. Biol. Chem. 271 (1996) 7712-7718
33. Drake R.R., Neamati N., Hong H., Pilon A.A., Sunthankar P., Hume S.D., et al. Identification of a nucleotide binding site in HIV-1 integrase. Proc. Natl Acad. Sci. USA 95 (1998) 4170-4175
34. Gao K., Butler S.L., and Bushman F. Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBO J. 20 (2001) 3565-3576
35. Jenkins T.M., Esposito D., Engelman A., and Craigie R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 16 (1997) 6849-6859
36. Esposito D., and Craigie R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J. 17 (1998) 5832-5843
37. Lutzke R.A., Vink C., and Plasterk R.H. Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res. 22 (1994) 4125-4131
38. Heuer T.S., and Brown P.O. Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry 37 (1998) 6667-6678
39. Agapkina J., Smolov M., Barbe S., Zubin E., Zatsepin T., Deprez E., et al. Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA. J. Biol. Chem. 281 (2006) 11530-11540
40. Guare J.P., Wai J.S., Gomez R.P., Anthony N.J., Jolly S.M., Cortes A.R., et al. A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 2900-2904
41. Embrey M.W., Wai J.S., Funk T.W., Homnick C.F., Perlow D.S., Young S.D., et al. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg. Med. Chem. Lett. 15 (2005) 4550-4554
42. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287 (2000) 646-650
43. Grobler J.A., Stillmock K., Hu B., Witmer M., Felock P., Espeseth A.S., et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA 99 (2002) 6661-6666
44. Marchand C., Zhang X., Pais G.C., Cowansage K., Neamati N., Burke Jr. T.R., and Pommier Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J. Biol. Chem. 277 (2002) 12596-12603
45. Pluymers W., Pais G., Van Maele B., Pannecouque C., Fikkert V., Burke Jr. T.R., et al. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob. Agents Chemother. 46 (2002) 3292-3297
46. Fikkert V., Hombrouck A., Van Remoortel B., De Maeyer M., Pannecouque C., De Clercq E., et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18 (2004) 2019-2028
47. Lee D.J., and Robinson Jr. W.E. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to l-chicoric acid. J. Virol. 78 (2004) 5835-5847
48. Lu R., Limon A., Ghory H.Z., and Engelman A. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J. Virol. 79 (2005) 2493-2505
49. Maertens G., Cherepanov P., Pluymers W., Busschots K., De Clercq E., Debyser Z., and Engelborghs Y. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem. 278 (2003) 33528-33539
50. Ciuffi A., Llano M., Poeschla E., Hoffmann C., Leipzig J., Shinn P., et al. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 11 (2005) 1287-1289
51. Emiliani S., Mousnier A., Busschots K., Maroun M., Van Maele B., Tempe D., et al. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem. 280 (2005) 25517-25523
52. Harper A.L., Skinner L.M., Sudol M., and Katzman M. Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. J. Virol. 75 (2001) 7756-7762
53. Lu R., Limon A., Devroe E., Silver P.A., Cherepanov P., and Engelman A. Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication. J. Virol. 78 (2004) 12735-12746
54. Jeltsch A., Wenz C., Wende W., Selent U., and Pingoud A. Engineering novel restriction endonucleases: principles and applications. Trends Biotechnol. 14 (1996) 235-238
55. Winkler F.K., Banner D.W., Oefner C., Tsernoglou D., Brown R.S., Heathman S.P., et al. The crystal structure of EcoRV endonuclease and of its complexes with cognate and non-cognate DNA fragments. EMBO J. 12 (1993) 1781-1795
56. Yang Z., Horton J.R., Maunus R., Wilson G.G., Roberts R.J., and Cheng X. Structure of HinP1I endonuclease reveals a striking similarity to the monomeric restriction enzyme MspI. Nucleic Acids Res. 33 (2005) 1892-1901
57. Johnson A.A., Santos W., Pais G.C., Marchand C., Amin R., Burke Jr. T.R., et al. Integration requires a specific interaction of the donor DNA terminal 5′-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J. Biol. Chem. 281 (2006) 461-467
58. Bischerour J., Leh H., Deprez E., Brochon J.C., and Mouscadet J.F. Disulfide-linked integrase oligomers involving C280 residues are formed in vitro and in vivo but are not essential for human immunodeficiency virus replication. J. Virol. 77 (2003) 135-141
59. Priet S., Navarro J.M., Querat G., and Sire J. Reversion of the lethal phenotype of an HIV-1 integrase mutant virus by overexpression of the same integrase mutant protein. J. Biol. Chem. 278 (2003) 20724-20730
60. Sayasith K., Sauve G., and Yelle J. Characterization of mutant HIV-1 integrase carrying amino acid changes in the catalytic domain. Mol. Cells 10 (2000) 525-532
61. Vincent K.A., Ellison V., Chow S.A., and Brown P.O. Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations. J. Virol. 67 (1993) 425-437
62. Puglia J., Wang T., Smith-Snyder C., Cote M., Scher M., Pelletier J.N., et al. Revealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteins. J. Virol. 80 (2006) 9497-9510
63. Yi J., Asante-Appiah E., and Skalka A.M. Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase. Biochemistry 38 (1999) 8458-8468
64. Hindmarsh P., Johnson M., Reeves R., and Leis J. Base-pair substitutions in avian sarcoma virus U5 and U3 long terminal repeat sequences alter the process of DNA integration in vitro. J. Virol. 75 (2001) 1132-1141
65. Brin E., and Leis J. Changes in the mechanism of DNA integration in vitro induced by base substitutions in the HIV-1 U5 and U3 terminal sequences. J. Biol. Chem. 277 (2002) 10938-10948
66. Brin E., and Leis J. HIV-1 integrase interaction with U3 and U5 terminal sequences in vitro defined using substrates with random sequences. J. Biol. Chem. 277 (2002) 18357-18364
67. Katzman M., Katz R.A., Skalka A.M., and Leis J. The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration. J. Virol. 63 (1989) 5319-5327
68. Harrison R.W. Stiffness and energy conservation in molecular dynamics: an improved integrator. J. Comput. Chem. 14 (1993) 1112-1122
69. Weber I.T., and Harrison R.W. Molecular mechanics calculations on HIV-1 protease with peptide substrates correlate with experimental data. Protein Eng. 9 (1996) 679-690
70. Weber I.T., and Harrison R.W. Molecular mechanics calculations on Rous sarcoma virus protease with peptide substrates. Protein Sci. 6 (1997) 2365-2374
71. Bagossi P., Zahucky G., Tozser J., Weber I.T., and Harrison R.W. Improved parameters for generating partial charges: correlation with observed dipole moments. J. Mol. Model 5 (1999) 143-152